** German drug containment and delivery systems maker Schott Pharma 1SXP.DE is upgraded to "buy" from "neutral" by UBS, which says two headwinds are abating
** The analyst expects the sector-wide vial destocking following the COVID pandemic to abate by mid 2025 at the latest noting positive developments in order intake
** Following last year's order cancellations the broker removes about EUR 90 million of mRNA polymer syringe sales from its estimates
** However, UBS still sees potential for growth in the glass syringe business on the back of capacity additions to more than offset the reduction in mRNA polymer syringe sales
** UBS says Schott trades at about a 30% discount to peer Stevanato STVN.N despite similar sales and profits three year compounded annual growth rates
** Out of 12 analysts that cover SCHOTT Pharma AG & Co KgaA, five rate the stock "strong buy" or "buy," four rate "hold" and three rate the stock "strong sell" or "sell"
(Reporting by Simon Ferdinand Eibach)
((Simonferdinand.eibach@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.